首页|循环肿瘤DNA在早期乳腺癌分子检测中的研究进展

循环肿瘤DNA在早期乳腺癌分子检测中的研究进展

扫码查看
通过常规检查方法(钼靶摄片、CT、超声)早期发现乳腺癌(BRCA)存在一定程度的局限,而液体活检技术在BRCA患者中的早期诊断优势日益显著。循环肿瘤DNA(ctDNA)是存在于体液中的部分游离于细胞外的DNA。ctDNA是以液体活检技术为基础的筛选新型肿瘤标志物的新思路,并有助于早期乳腺癌的临床决策。本研究就ctDNA的生物学特性、检测方法在早期BRCA诊治中的应用进行探讨,并展望ctDNA的未来研究方向。
Research progress of circulating tumor DNA in molecular detection of early breast cancer
Breast cancer(BRCA)is the most common malignant tumor in the world and the leading cause of death in female patients.In addition,early detection of BRCA by conventional screening methods(mammography,CT,ultrasound)is limited to a certain extent,and liquid biopsy technology has become increasingly advantageous for the early diagnosis of BRCA patients.Circulat-ing Tumor DNA(ctDNA)is a partially free extracellular DNA present in body fluids.The ctDNA is a new idea for screening novel tumor markers based on liquid biopsy technology and helps in clinical decision-making for early breast cancer.In this paper,we discussed the biological properties of ctD-NA,detection methods,and its application in the diagnosis and treatment of early BRCA,and we al-so look forward to the future research direction of ctDNA.

early breast cancercirculating tumor DNAliquid biopsybiomarkers

石钰、徐澍

展开 >

贵州医科大学临床医学院,贵州贵阳,550000

贵州医科大学附属医院病理科,贵州贵阳,550000

早期乳腺癌 循环肿瘤DNA 液体活检 生物标志物

贵州医科大学国家自然科学基金培育项目

I-2020-18

2024

实用临床医药杂志
扬州大学,中国高校科技期刊研究会

实用临床医药杂志

CSTPCD
影响因子:1.543
ISSN:1672-2353
年,卷(期):2024.28(16)
  • 1